Quest Diagnostics Inc (DGX)
150.46
-2.15 (-1.41%)
USD |
NYSE |
Dec 02, 16:00
150.43
-0.03 (-0.02%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 17.14B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -0.58% |
| Valuation | |
| PE Ratio | 14.79 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 1.743 |
| Price to Book Value | 2.748 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.66 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.6387 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 36.60% |
News
Headline
Wire
Time (ET)
MT Newswires
12/01 14:42
Yahoo
12/01 09:53
Yahoo
12/01 08:42
Yahoo
11/29 13:20
PR Newswire
11/28 09:25
Yahoo
11/22 10:45
Yahoo
11/18 06:02
SA Breaking News
11/17 12:41
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 02/03/2023* | -- | Results | Q4 2022 | -- | 1.89 | -- | |
| 02/03/2023* | -- | Earnings Call | Q4 2022 | -- | -- | -- | |
| 10/20/2022 | -- | Results | Q3 2022 | -- | 2.18 | -- | |
| 10/20/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
| 07/21/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
| 07/21/2022 | -- | Results | Q2 2022 | 2.36 | 2.27 | 3.91% | |
| 04/21/2022 | -- | Results | Q1 2022 | 3.22 | 3.00 | 7.26% | |
| 04/21/2022 | 08:30 EST | Earnings Call | Q1 2022 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions. |
| URL | https://www.questdiagnostics.com |
| Investor Relations URL | https://ir.questdiagnostics.com/overview/default.aspx |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Feb. 03, 2023 (est.) |
| Last Earnings Release | Oct. 20, 2022 |
| Next Ex-Dividend Date | Jan. 17, 2023 |
| Last Ex-Dividend Date | Oct. 03, 2022 |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | 2.60 |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 1.337 |
| Yield to Sector | 1.155 |
| Yield to Industry | 5.085 |
| Last Dividend Amt. | 0.66 |
| Dividend Frequency | Quarterly |
| Last Ex-Dividend Date | Oct. 03, 2022 |
| Yield (TTM) | 1.73% |
| Forward Yield | 1.75% |
| Payout Ratio | 24.86% |
| Cash Payout Ratio | 20.97% |
| Consistent Payer (5Y) |
|
| Consistent Growth (5Y) |
|
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of December 02, 2022.
Fundamentals
| Revenue (TTM) | 10.29B |
| Total Expenses (TTM) | 8.465B |
| Net Income (TTM) | 1.235B |
| Total Assets (Quarterly) | 13.22B |
| Total Liabilities (Quarterly) | 6.874B |
| Shareholders Equity (Quarterly) | 6.235B |
| Cash from Operations (TTM) | 1.865B |
| Cash from Investing (TTM) | -596.00M |
| Cash from Financing (TTM) | -1.556B |
Ratings
Profile
Edit
| Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions. |
| URL | https://www.questdiagnostics.com |
| Investor Relations URL | https://ir.questdiagnostics.com/overview/default.aspx |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Equity Style | Mid Cap/Value |
| Next Earnings Release | Feb. 03, 2023 (est.) |
| Last Earnings Release | Oct. 20, 2022 |
| Next Ex-Dividend Date | Jan. 17, 2023 |
| Last Ex-Dividend Date | Oct. 03, 2022 |
Risk Info
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Top Fund Holders
| Symbol | Dollars Invested | % Weight |
|---|---|---|
| IHF | 52.45M USD | 3.25% |
| ATL1364 | 44.35M USD | 2.16% |
| ACCLX | 173.09M USD | 2.06% |
| ALVGX | 53.09M USD | 1.77% |
| VEVCX | 256.42M USD | 1.75% |
| RYH | 16.91M USD | 1.74% |
| FXH | 26.49M USD | 1.72% |
| SPGP | 25.31M USD | 1.51% |
| SHISX | 119.46M USD | 1.35% |
| ZLU.TO | 18.03M USD | 1.30% |
| PLASX | 46.26M USD | 1.27% |
| FTA | 12.00M USD | 0.93% |
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| DGX Tweets |